NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.27 -0.07 (-2.99 %)
(As of 01/16/2019 04:00 PM ET)
Previous Close$2.34
Today's Range$2.26 - $2.34
52-Week Range$1.83 - $18.00
Volume38,055 shs
Average Volume197,276 shs
Market Capitalization$7.84 million
P/E Ratio-0.13
Dividend YieldN/A
Beta-0.37
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.

Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DFFN
CUSIPN/A
Phone434-220-0718

Debt

Current Ratio12.30
Quick Ratio12.30

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash Flow$2.5795 per share
Price / Cash Flow0.88
Book Value$6.30 per share
Price / Book0.36

Profitability

Net Income$-1,360,000.00
Net MarginsN/A
Return on Assets-24.11%

Miscellaneous

Employees11
Market Cap$7.84 million
OptionableNot Optionable

Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work?

Diffusion Pharmaceuticals shares reverse split on the morning of Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) released its earnings results on Wednesday, November, 14th. The company reported ($1.95) EPS for the quarter, missing the consensus estimate of ($0.90) by $1.05. View Diffusion Pharmaceuticals' Earnings History.

When is Diffusion Pharmaceuticals' next earnings date?

Diffusion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Diffusion Pharmaceuticals.

What price target have analysts set for DFFN?

1 equities research analysts have issued 1 year target prices for Diffusion Pharmaceuticals' shares. Their predictions range from $15.00 to $15.00. On average, they anticipate Diffusion Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 560.8% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.

What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.

Has Diffusion Pharmaceuticals been receiving favorable news coverage?

News coverage about DFFN stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near term.

Are investors shorting Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals saw a decrease in short interest in the month of December. As of December 14th, there was short interest totalling 69,748 shares, a decrease of 90.1% from the November 30th total of 707,303 shares. Based on an average daily trading volume, of 113,994 shares, the days-to-cover ratio is currently 0.6 days. Approximately 2.2% of the shares of the company are short sold. View Diffusion Pharmaceuticals' Current Options Chain.

Who are some of Diffusion Pharmaceuticals' key competitors?

Who are Diffusion Pharmaceuticals' key executives?

Diffusion Pharmaceuticals' management team includes the folowing people:
  • Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)
  • Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)
  • Mr. William Karl Hornung, Chief Financial Officer (Age 50)
  • Mr. Thomas E. Byrne, Gen. Counsel (Age 62)
  • Dr. David Randolph Jones M.D., Chief Medical Officer (Age 56)

Who are Diffusion Pharmaceuticals' major shareholders?

Diffusion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.54%).

Which institutional investors are selling Diffusion Pharmaceuticals stock?

DFFN stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $2.27.

How big of a company is Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals has a market capitalization of $7.84 million. The company earns $-1,360,000.00 in net income (profit) each year or ($17.09) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe.

What is Diffusion Pharmaceuticals' official website?

The official website for Diffusion Pharmaceuticals is http://www.diffusionpharma.com.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]


MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel